



In Search of More Effective and Less Invasive Ways to Treat Esophagus and Stomach Cancer

Guest Editors:

Dr. Peter Thuss-Patience

Department of Hematology,
Oncology and Cancer-
Immunology, Charité – University
Medicine Berlin, Augustenburger
Platz 1, 13353 Berlin, Germany

Prof. Dr. Matthias Biehl

Department of Surgery, Campus
Virchow Klinikum/Campus
Charite Mitte, Charite University
Medicine Berlin, Augustenburger
Platz 1, 13353 Berlin, Germany

Dr. Severin Daum

Department of Gastroenterology,
Rheumatology und Infectious
Diseases, Campus Benjamin
Franklin, Charité – University
Medicine Berlin,
Hindenburgdamm 30, 12 203
Berlin, Germany

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editors

In the last 3 to 5 years, treatment options for esophago-gastric cancer have been rapidly changing. New molecular subgroups with clinical significance have been identified, new targets have been discovered, and promising specific antibodies have been designed. Phase III data have changed treatment algorithms in perioperative, adjuvant and palliative settings. Technical innovations have optimized endoscopic treatment; minimally invasive and robotic surgery techniques are becoming more and more advanced.

This Special Issue is looking for original manuscripts and reviews to explore all areas of treatment, including: Screening and genetic syndromes; Molecular classification, prognostic and predictive biomarkers; New options for endoscopic treatment; New approaches to optimize perioperative and adjuvant strategies; New ways to optimize surgical techniques; Individualized treatment strategies in the palliative setting; Novel combinations for palliative therapy; Developments in immunotherapy and beyond.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

Journal Rank: JCR - Q2 (*Oncology*)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currnocol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)